Since the discovery of induced pluripotent stem cell (iPSC) technology 18 years ago, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. [Read more…]
Custom iPSC Engineering Services – 4 Reasons to Choose Applied StemCell
Applied StemCell Inc. (ASC) is a gene-editing company that offers an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications. Currently, the company is focused on the following areas:
- Cell line generation for bio-production and bioassays
- Patient-relevant cell models for personalized medicine
- Physiologically predictive animal and cellular models of human disease
Applied StemCell uses its TARGATT™ technology to specifically insert a gene-of-interest at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression. This site-specific knock-in technology was first established in mouse models, and ASC has successfully applied it to human cell lines.
ASC has leveraged this technology across various projects that combine the complementary CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression. [Read more…]
The Present and Future Trajectory of the Cord Blood & Tissue Banking Market
Umbilical cord blood (UCB) has been an accepted source of hematopoietic stem cells (HSC) for transplantation for more than 30 years. Umbilical cord-derived stem cells are the youngest cells available for transfusion and yet their uptake lags behind bone marrow and peripheral blood-derived HSCs. Decreased engraftment rates and the low cell dose available for transplantation are limitations that are preventing umbilical cord blood-derived cells from reaching their full potential. While a handful of companies are now developing cord blood and tissue-derived cell therapeutics, it will likely take several years for these products to reach commercialization. [Read more…]
Bio-Techne Files Drug Master File For ExCellerate GMP iPSC Expansion Medium to Support Manufacture of Stem Cell Therapies
MINNEAPOLIS, MN, December 20, 2023 — Bio-Techne Corporation (NASDAQ: TECH) has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ExCellerate™ GMP iPSC Expansion Medium, Animal Free (CCM0036-GMP), supporting the development and manufacture of regenerative medicine and stem cell therapies. [Read more…]
Recent Breakthroughs in Using Platelet-Rich Plasma (PRP) for Veterinary Applications
Platelet-rich plasma (PRP) therapy is blood plasma that has been enriched with platelets, using a process of standard whole blood collection, followed by anticoagulation (usually with citrate dextrose), and finally, centrifugation. This process separates the platelet-rich plasma (PRP) component of the blood from the red blood cells and other non-therapeutic components, producing a concentrated source of self-derived (“autologous”) platelets as the final PRP product.
This resulting PRP component contains both growth factors and cytokines that may have the ability to support or stimulate the healing of bone, as well as soft tissue structures, such as ligaments, tendons, fascia, and more. While there have not yet been large-scale, controlled clinical trials conducted to evaluate the efficacy of PRP, the procedure has nonetheless become commonplace in medical offices worldwide, most notably, within orthopedic offices. [Read more…]
- « Previous Page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- …
- 202
- Next Page »




